Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease

被引：48

作者：

Rissman, Robert A. ^{[1
]}

Trojanowski, John Q. ^{[2
]}

Shaw, Leslie M. ^{[2
]}

Aisen, Paul S. ^{[1
]}

机构：

[1] UCSD, Alzheimers Dis Cooperat Study, Dept Neurosci, Sch Med, La Jolla, CA 92037 USA

[2] Univ Penn, Sch Med, Dept Pathol & Lab Med, Inst Aging,Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA

来源：

JOURNAL OF NEURAL TRANSMISSION | 2012年 / 119卷 / 07期

关键词：

Alzheimer's disease; Protein biomarker; Plasma amyloid; RECEPTOR-RELATED PROTEIN-1; MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID; PRECURSOR PROTEIN; DENSITY-LIPOPROTEIN; MOUSE MODEL; BRAIN; PEPTIDE; ASSOCIATION; RISK;

D O I：

10.1007/s00702-012-0772-4

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Alzheimer's disease (AD) affects more than twenty-five million people worldwide and is the most common form of dementia. Symptomatic treatments have been developed, but effective intervention to alter disease progression is needed. Targets have been identified for disease-modifying drugs, but the results of clinical trials have been disappointing. Peripheral biomarkers of disease state may improve clinical trial design and analysis, increasing the likelihood of successful drug development. Amyloid-related measures, presumably reflecting principal pathology of AD, are among the leading cerebrospinal fluid and neuroimaging biomarkers, and measurement of plasma levels of amyloid peptides has been the focus of much investigation. In this review, we discuss recent data on plasma beta-amyloid (A beta) and examine the issues that have arisen in establishing it as a reliable biomarker of AD.

引用

页码：843 / 850

页数：8

共 58 条

[1] β-amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease [J].

Andreasen, N ;

Blennow, K .

PEPTIDES, 2002, 23 (07) :1205-1214

[2] EXPRESSION PATTERNS OF BETA-AMYLOID PRECURSOR PROTEIN (BETA-APP) IN NEURAL AND NONNEURAL HUMAN TISSUES FROM ALZHEIMERS-DISEASE AND CONTROL SUBJECTS [J].

ARAI, H ;

LEE, VMY ;

MESSINGER, ML ;

GREENBERG, BD ;

LOWERY, DE ;

TROJANOWSKI, JQ .

ANNALS OF NEUROLOGY, 1991, 30 (05) :686-693

[3] Serum creatinine levels correlate with plasma amyloid β protein [J].

Arvanitakis, Z ;

Lucas, JA ;

Younkin, LH ;

Younkin, SG ;

Graff-Radford, NR .

ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2002, 16 (03) :187-190

[4] Fluctuations of CSF amyloid-β levels -: Implications for a diagnostic and therapeutic biomarker [J].

Bateman, Randall J. ;

Wen, Guolin ;

Morris, John C. ;

Holtzman, David M. .

NEUROLOGY, 2007, 68 (09) :666-669

[5] Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma [J].

Biere, AL ;

Ostaszewski, B ;

Stimson, ER ;

Hyman, BT ;

Maggio, JE ;

Selkoe, DJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (51) :32916-32922

[6] Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: Prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine [J].

Blasko, Imrich ;

Jellinger, Kurt ;

Kemmler, Georg ;

Krampla, Wolfgang ;

Jungwirth, Susanne ;

Wichart, Ildigo ;

Tragl, Karl Heinz ;

Fischer, Peter .

NEUROBIOLOGY OF AGING, 2008, 29 (01) :1-11

[7] Amyloid β and Alzheimer disease therapeutics:: the devil may be in the details [J].

Cirrito, JR ;

Holtzman, DM .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (03) :321-323

[8]

Coppus AM, 2011, NEUROBIOL AGING

[9] RAGE (Yin) versus LRP (Yang) balance regulates Alzheimer amyloid β-peptide clearance through transport across the blood-brain barrier [J].

Deane, R ;

Wu, ZH ;

Zlokovic, BV .

STROKE, 2004, 35 (11) :2628-2631

[10] LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms [J].

Deane, R ;

Wu, ZH ;

Sagare, A ;

Davis, J ;

Yan, SD ;

Hamm, K ;

Xu, F ;

Parisi, M ;

LaRue, B ;

Hu, HW ;

Spijkers, P ;

Guo, H ;

Song, XM ;

Lenting, PJ ;

Van Nostrand, WE ;

Zlokovic, BV .

NEURON, 2004, 43 (03) :333-344

← 1 2 3 4 5 6 →